Business Editors/Health & Medical Writers
BIOWIRE2K
BERKELEY, Calif.--(BUSINESS WIRE)--Sept. 30, 2002
Dr. Mark Ptashne has joined the scientific advisory board of Auilix Biopharma, Inc. Dr. Ptashne is a principle investigator at the Memorial Sloan-Kettering Cancer
Auilix is exploiting the field of regulatory genomics to accelerate the discovery of novel, small-molecule therapeutics for our most significant diseases. The Auilix drug discovery engine is a unique and integrated system for discovering key regulatory modules, such as enhancers, relevant to a disease-related pathway. By using these DNA modules, Auilix is engineering multi-dimensional assay systems to screen with unprecedented speed and reliability for lead compounds that most effectively target the particular pathway. The same assay system allows Auilix to pinpoint the drug-targeted protein and other proteins in the pathway, thereby assembling the complete mechanism of action.
Dr. Ptashne joins the Auilix Scientific Advisory Board which is composed of leaders in the field of gene regulation or "regulatory genomics." The Board includes Dr. Michael Levine, Dr. Eric Davidson, Dr. Cornelis Murre and Dr. Donald Rio. Dr. Levine, Professor of Genetics at UC Berkeley, as well as a member of the National Academy of Sciences, has worked to elucidate combinatorial regulation at complex enhancers, which are modular DNA sequences involved in the transcriptional control of genes. Dr. Davidson, Professor of Biology at the California Institute of Technology and a member of the National Academy of Sciences, has been a pioneer and leader in the field of gene regulation since it's inception and is the author of the text books "Gene Activity in Early Development" and "Genomic Regulatory Systems." Dr. Murre, Professor of Biology at UC San Diego, has been working on gene transcriptional control involved in the differentiation of cells of the immune system. Dr. Rio, Professor of Genetics at UC Berkeley, brings deep expertise in molecular biology, biochemistry and modern developments in biotechnology.